Markov model and markers of small cell lung cancer: Assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis

British Journal of Cancer

Volumn 79, Issue 9-10, 1999, Pages 1419-1427

  Boher, J M ^a   Pujol, J L ^a,b   Grenier, J ^c   Daures J P ^a  

^a UNIV MONTPELLIER   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c Laboratoire de Radio Analyses   (France)

Author keywords

CYFRA 21 1; Markov model; NSE; Prognosis; Small cell lung cancer; TPS; Tumour response

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MODEL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS;

EID: 0032975968     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690227     Document Type: Article

References (22)

1. Andersen PK, Hansen LS and Keiding N (1991) Assessing the influence of reversible disease indicators on survival. Stat Med 10: 1061-1067
2. Bales SE (1991) Clinical applications of serum tumour markers. Ann Intern Med 115: 623-638
3. Cooper EH, Splinter TAW and Brown DA (1985) Evaluation of a radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 52: 333-338.
4. Cox DR (1972) Regression models and life tables. J Roy Stat Soc B 34: 187-220
5. Gentleman RC, Lawless JF, Lindsey JC and Yan P (1994) Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. Stat Med 13: 805-821
6. Grüger J, Kay R and Schumacher M (1991) The validity of inferences based on incomplete observations in disease state models. Biometrics 47: 595-605
7. Hansen HH and Kristjansen PEG (1991) Chemotherapy of small cell lung cancer. Eur J Cancer 27: 342-349
8. Iannuzzi MC and Seoggin CH (1986) State of the art: small cell lung cancer. Am Rev Res Dis 134: 593-608
9. Jørgensen LGM, Osterlind K, Hansen HH and Cooper EH (1988) The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer 58: 805-807
10. Jørgensen LGM, Hansen HH and Cooper EH (1989) Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol 25: 123-128
11. Kalbfleish JD and Prentice RL (1980) The Statistical Analysis of Failure Time Data. Wiley: New York
12. Kalbfleish JD and Lawless JF (1985) The analysis of panel data under a Markov assumption. JASA 80: 863-871
13. Kay R (1986) A Markov model for analysing cancer markers and disease states in survival studies. Biometrics 42: 855-865
14. Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H and Michel FB (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61-66
15. Pujol JL, Cooper EH, Grenier J, Purves DA, Lehmann M, Ray P, Dan Aouta M, Bashir M, Godard P and Michel FB (1994) Clinical evaluation of serum TPS in non-small cell lung cancer. Eur J Cancer 30A: 1768-1774
16. Pujol JL, Greníer J, Parrat E, Lehmann M, Lafontaine M. Quantín X and Michel FB (1996a) Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Res Crit Care Med 154: 725-732
17. Pujol JL, Parrat E, Lehmann M, Gautier V, Daurès JP, Michel FB and Godard P (1996b) Lung cancer chemotherapy: methods of response evaluation and response-survival relationship. Am J Res Crit Care Med 153: 243-249
18. Sobin LH, Hermanek, P and Hutter, RVP (1987) TNM Classification of Malignant Tumours, 4th edn. UICC: Geneva
19. Tisi GM, Friedman PJ, Peters RM, Pearson G, Carr D, Lee RE and Selawry O (1982) American Thoracic Society: clinical staging of primary lung cancer. Am Rev Res Dis 125: 659-664
20. Van Der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F and Splinter TAW (1994) Evaluation of a new tumour marker in patients with non-small cell lung cancer: CYFRA 21-1. Br J Cancer 69: 525-528
21. World Health Organization (1979) WHO Handbook for Reporting the Results of Cancer Treatment. WHO Offset Publication, 48: Geneva
22. World Health Organization (1982) The World Health Organization histological typing of the lung tumours, 2nd edn. Am J Clin Pathol 77: 123-136